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Summary From 1975 to 1988, 144 patients naive of treatment, with non-metastatic soft tissue sarcoma were
treated at Fondation Bergonie by surgery, followed by radiotherapy and without chemotherapy. An analysis
of prognostic variables was done on this population to determine patients for whom an adjuvant
chemotherapy would be relevant. Prognostic variables in overall survival (OS), metastasis-free survival (MFS),
disease-free and local free recurrence survivals were analysed by univariate and multivariate analysis. In
multivariate analysis using Cox's model, only tumour depth and tumour grade were significant with the MFS
end point, while tumour depth, tumour grade and tumour site were significant when considering OS. A
predictive stratification for patients is proposed: a favourable prognostic group with grade 1 tumour or
superficial, grade 2 tumour (5-year OS: 97.8%; 5-year MFS: 100%); an intermediate prognostic group with
deep, grade 2 tumour or superficial, grade 3 tumour (5-year OS: 58.8%; 5-year MFS: 48.1%); and finally a
poor prognostic group with deep, grade 3 tumour (5-year OS: 31.7%; 5-year MFS: 34.1%). Patients in the
intermediate and poor prognostic groups who present a high metastatic risk are to be considered for adjuvant
chemotherapy trials.
Soft tissue sarcomas (STS) are rare tumours, as they account
for 0.7% of all malignant disease in adults. They represent an
heterogeneous group of tumours which are histologically
classified by their supposed histogenesis. At present, more
than 60 types and subtypes are recognised (Enterline, 1981;
Enzinger, 1983; Hadju, 1979).
The main advances achieved in the management of STS
have been in the field of local control, which can now be
obtained in approximately 80% of cases, despite important
remaining problems such as the treatment of particular loca-
tions - such as the head, neck and retroperitoneum - the
respective value of radical surgery versus less than radical
surgery plus radiotherapy (Enneking et al., 1981; Enneking
1983; Rosenberg et al., 1982), optimal radiation therapy
techniques (Lagarde et al., 1990; Suit et al., 1985), or the role
of a preoperative treatment (Lagarde et al., 1988; Rouesse et
al., 1987). Therefore, one can consider that survival of
patients with STS is mainly related to the metastatic risk of
their disease. However, this metastatic evolution is widely
variable from one tumour to another even within a same
tumour type.
Many prognostic classifications of STS have been devel-
oped according to different evaluation ofprognostic variables
(Enzinger, 1983; Hajdu, 1979; Russell et al., 1977). The AJC
system is the most widely used, but was established by a
retrospective study, and whether this system is predictive in
contemporary patients remains questionable (Presant et al.,
1986; Russell et al., 1977). Moreover, the predictive value of
this classification for metastatic recurrences in the particular
group of operable patients is unclear. Therefore, its suita-
bility in selecting poor risk patients to whom adjuvant
chemotherapy could be given has not been assessed.
This study was undertaken in a series of patients referred
for their first treatment to one institution and managed with
an homogeneous strategy for local treatment and without
adjuvant chemotherapy. Only operable patients were con-
sidered to determine the poor prognostic group to be even-
tually selected for adjuvant treatment (Bui et al., 1989;
Ravaud et al., 1990).
Patients and methods
Patient selection
From 1975 to 1988, 381 patients were referred to Fondation
Bergonie (FB) for STS proven by a systematic histological
review. Visceral sarcomas were not considered here. Forty-
one presented with overt metastatic disease, 123 had a local
recurrence after a previous treatment outside FB. The re-
maining 217 patients were referred for a non-metastatic and
until then untreated primary. In 32 patients, a preoperative
chemotherapy was performed. Moreover, 44 patients received
adjuvant chemotherapy after resection of their primary; these
patients were excluded. The remaining 141 patients were
considered for this study because they were those for whom
an adjuvant chemotherapy could prove effective, as they
were: (1) naive of treatment, (2) primarily treated by surgery,
(3) treated and followed at a single institution, (4) without
adjuvant or neoadjuvant chemotherapy.
Patient characteristics
All patients were free of metastatic disease at initial work-up
which included lung tomograms before 1978, and pulmonary
CAT scan after 1978. The following data were analysed from
each chart: (1) patient characteristics including sex and age;
(2) tumour characteristics including site, size, depth, invasion
of neurovascular structures or bone, histopathology, grade,
node involvement; (3) treatment characteristics including sur-
gical procedure and results of surgery; (4) evolution including
date of first local and first metastases, and status at last
follow-up visit.
The histologic slides of all patients entered were reviewed
at our institution by one pathologist. Immunohistochemistry
was extensively used for confirmation of the diagnosis of
sarcoma or for tumour typing. Tumour grade was evaluated
according to the system of the French Federation of Cancer
Centers (FNCLCC) based on scores obtained in the evalua-
tion of tumour differentiation, necrosis score and mitotic
count (Trojani et al., 1984; Coindre et al., 1986). For statis-
tical analysis evaluating Hadju's classification, grade was
defined as low with FNCLCC total grading scores from 2 to
4 and as high with FNCLCC total grading scores from 5 to
8. Tumours from all sites were considered providing a
tumour excision was done primarily. Extremity tumours were
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subsequently divided into proximal or distal tumours at
analysis. Tumours of trunk wall and those from deeper loca-
tions, such as the retroperitoneum, pelvis or mediastinum
were analysed separately. Tumour size was defined as the
largest tumour diameter measured either on CAT scan or on
the excised specimen. A tumour situated beneath or involving
the superficial fascia was considered as deep, and a tumour
above the fascia as superficial. According to these charac-
teristics, the tumours were classified according to both AJC/
UICC and Hajdu's classifications.
Patients
Of the 141 patients, there were 77 males and 64 females, aged
from 16 to 87 with a median of 50.3 years. The primary
tumours were located in head and neck in 14 patients, prox-
imal extremities in 52, distal extremities in 29, mediastinum,
retroperitoneum or pelvis in 22, trunk wall including limb
girdles in 24. Tumour size was less than 5 cm in only 47
patients and equal to or larger than 5 cm in 88. Forty
tumours were superficial and 99 were deep. Gross or micro-
scopic invasion of neurovascular structures or bone was pres-
ent in 17 patients. Histologic types are listed in Table I with
malignant fibrous histiocytoma and liposarcoma predom-
inating. There were 30 grade 1 tumours, 67 grade 2 and 43
grade 3. Histologically confirmed involvement of regional
nodes was present in only one patient. According to TNM
staging, 43 patients were classified as Tl, 78 as T2, 17 as T3.
According to AJC/UICC staging, 29 patients were classified
as stage I, 56 as stage II, 37 as stage III and 17 as stage IVa.
According to Hajdu's system, 15 patients were classified as
stage 0, 21 patients as stage I, 52 as stage II, 44 as stage III.
Post-operative radiation therapy was not given in 31
patients: five because an amputation was performed, 18 who
had wide resection of a superficial tumour and eight who had
retroperitoneal tumours for which adequate post-operative
irradiation was considered impossible. The target volume was
planned according to pre-operative clinical examination and
CT scans, surgical conditions and histopathological results.
For each case, this included the tumour bed and all the
tissues handled during surgery, such as scars or drain
courses. The volume considered was an anatomical compart-
ment whenever possible. In the other cases, the usual margins
around the tumour-bed were 5 to 7 cm on all sides. Minimal
margins could be reduced to 3 to 5 cm for particular loca-
tions such as abdominal or retroperitoneal tumours. On the
other hand, the margins were enlarged for tumour patterns
with a known risk of microscopic extension. Dose depended
on the location of the tumour. Thus, for limb tumours and
parietal lesions of the head and neck or trunk, doses were
50 Gy in 25 fractions for 5 weeks in a volume described
above, with a boost of 10 Gy to 15 Gy restricted to the
tumour bed. Split courses were not performed. The total dose
to the final volume was 60 Gy to 65 Gy. For retroperitoneal
or deep-seated abdominal tumours, the dose was reduced to
40 Gy in 25 fractions over 5 weeks with a 10 Gy boost to the
tumour bed. Technical aspects of radiation treatment were
discussed for each case. High energy X-rays (18 MV and
25 MV), Co' photon and electrons were available. Opposing
fields were treated at each fraction. Simulation, portal films,
and CT scan reconstitution were performed. Dose was ex-
pressed at the ICRU point, but isodose distribution curves
were performed to avoid underdosage of the target volume.
Local treatment
Surgery was the first treatment in all patients. The policy was
to drastically limit amputations to patients with a major
osseous or vasculonervous involvement considered inaccessi-
ble to 'en-bloc' resection. Compartmental surgery was not
used. Wide resection, consisting of an excision of the tumour
and the biopsy scar with a margin of a few centimeters of
macroscopically normal tissue, was used whenever possible.
Marginal resection was defined as an operation in which this
margin of normal tissue could not be obtained at every point
on the tumour periphery, owing either to tumour location or
to the need to preserve a major vasculonervous axis or bone,
adherent to the tumour but not macroscopically involved.
Regional lymph node dissection was performed only in
patients with an involvement proven by cytologic examina-
tion of a suspect node. For patients referred after tumour
removal elsewhere, decision for reexcision was considered for
each case, after clinical and radiological reevaluation of the
local status, and after discussion with patients and referring
physicians. However, reexcision was systematic in patients
addressed 30 days or more after the initial surgery.
Consequently, the surgical procedures were amputation for
only five patients, marginal resection in 64, and wide resec-
tion in 72. For seven patients, macroscopic tumour residues
were left.
Table I Histologic types and grades
I II III Unknown Total (%)
Malignant fibrous histiocytoma 7 18 9 0 34 (24.1)
Liposarcoma 8 11 3 0 22 (15.6)
Leiomyosarcoma 8 9 2 0 19 (13.5)
Neurosarcoma 5 10 3 0 18 (12.8)
Undifferentiated sarcoma 0 3 13 0 16 (11.3)
Synovial sarcoma 0 10 3 0 13 (9.2)
Fibrosarcoma 1 4 4 1 10 (7.1)
Angiosarcoma 1 1 1 0 3 (2.1)
Rhabdomyosarcoma 0 0 2 0 2 (1.4)
Extraskeletal Osteosarcoma 0 0 2 0 2 (1.4)
Neuroepithelioma 0 0 1 0 1 (0.7)
Clear cell sarcoma 0 1 0 0 1 (0.7)
Figure 1 Overall survival and disease-free survival - all patients.
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Figure 2 Metastasis-free survival and local recurrence-free sur-
vival - all patients.
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Follow-up andstatistics
Follow-up consisted in clinical examination with chest X-ray
every 2 months for 2 years, then every 4 months for 3 years,
then every year. Abdominal ultrasonography were also per-
formed in patients with intraperitoneal and abdominal tu-
mours. Relapse or metastases was documented by biopsy or
unequivocal radiographic findings.
No patient was lost for follow-up. Survival, disease-free
survival, and local or metastatic recurrence-free survival were
computed by the Kaplan Meier method (Kaplan, 1958). The
initiation of treatment was considered as the time of origin.
Death whatever the cause was considered as the event for
overall survival studies, recurrence (local and/or metastatic)
for disease-free survival, local recurrence for local recurrence-
free survival and metastatic recurrence for metastasis-free
survival.
For each variable in the univariate analysis, we used either
the log-rank test (Peto, 1972) when two modalities of the
variable were compared, or a test for trend (Peto, 1977) when
three modalities were tested. Each variable was studied for
each of the following end points: local recurrence, metastatic
recurrence and overall survival. The variables, with P value
<0.10 in the univariate analysis, were included in Cox's
models (Cox, 1972) (program 2L of BMDP statistical soft-
ware). A stepwise procedure using MPLR (maximum partial
likehood ratio) made it possible to summarise the prognostic
information with the most pertinent variables. If a, are the
estimated coefficients for the final model and Xi the value of
the ith independent variable for the patient j, a score Sj can be
computed as follows:
Sj = a, XI + a2 X2 + ... + an Xn
This defined score makes it possible to rank each patient on
a scale with an increasing risk. Score values may be delimited
to determine different prognostic groups.
Results
With a median follow-up of 57.6 months (range 11-168
months), 11 patients (7.8%) died from a cause unrelated to
the treated sarcoma: cardiac or vascular disease: four; cere-
bral palsy: one, pulmonary infection: one; diabetes mellitus:
one; suicide: one; other cancer: three (osteosarcoma, colon
cancer, renal cancer); three of these patients presented a local
recurrence and one a metastatic spread. These patients were
excluded from the overall survival analysis but not from
disease-free or metastasis-free survival evaluations. At their
last follow-up visit, 90 patients were alive without evidence of
disease (63.8%), six were alive with recurrence (4.3%), 34
had died from STS (24.1%); for the entire series, the
actuarial 5-year overall survival rate was 66.1% (Figure 1);
the disease-free 5-year survival rate was 51.4% (Figure 1); the
metastasis-free 5-year survival rate was 63.2% (Figure 2) and
the local recurrence-free 5-year survival rate was 73.1%
(Figure 2).
Univanate analysis (Table II)
Age and sex did not affect patient evolution, although there
was a trend for a better local recurrence-free survival in male
patients (P = 0.06).
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Figure 4 Disease-free (DFS) and metastasis-free (MFS) survival
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Figure 6 Metastasis-free survival according to grade. Grade 1
(30 pts), grade 2 (67 pts), grade 3 (43 pts).
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Location Overall survival was significantly better in patients
with limb primaries compared to patients with non-limb
tumours (P = 0.05). However, there was no difference regar-
ding local control or metastasis-free survival. The only point
which could explain a difference only in overall survival was
a significantly better outcome after rescue treatment in
patients with an extremity tumour who first experienced a
relapse. For limb tumours, no significant difference was
observed regarding a proximal or distal location.
Tumour size The median largest tumour diameter in this
series was 8.2 cm (range 1-40 cm). Patients with tumours less
than 5 cm had a significantly better overall survival (P
= 0.01), disease-free survival (P = 0.006) and metastasis-free
survival (P = 0.03) than those with a tumour of 5 cm or
more. There was no significant difference in terms of local
recurrence-free survival (P = 0.14).
Invasion of neurovascular structures or bone Patients with
such an invasion had a significantly worse prognostic in
overall survival (P = 0.003), disease-free survival (P = 0.003)
and metastasis-free survival (P = 0.007) than those without
invasion.
T staging Owing to differences according to tumour size
and local invasion, there was a significant difference in evolu-
tion between T1, T2, T3 lesions, as defined by the AJC
staging system, except for local recurrence-free survival.
Tumour depth Tumour depth had a significant impact on
prognostic. Patients with superficial lesions had a signifi-
cantly better overall survival (P = 0.003) (Figure 3), disease-
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Figure 7 Overall survival according to stage (AJC/UICC
classification). Stage I (29 pts), stage 11(56 pts), stage III (37 pts),
stage IVa (17 pts).
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Figure 8 Metastasis-free survival according to stage (AJC/UICC
classification). Stage 1 (29 pts), stage 11(56 pts), stage III (37 pts),
stage IVa (17 pts).
free survival (P = 0.005) and metastasis-free survival (P
= 0.0003) (Figure 4) than those with deep tumours. Tumour
depth did not affect local control.
Histopathology Sixty-five per cent of the tumours could be
classifed into four histopathological types: malignant fibrous
histocytoma (MFH) (24.1%), liposarcoma (15.6%), leiomyo-
sarcoma (13.5%), undifferentiated sarcoma (11.3%). Three
spindle cell sarcomas were classified as undifferentiated sar-
coma and were classified as grade 2 tumours. In this series,
the 5-year overall survival was over 65% for patients with
the following tumours: MFH (82.7%), liposarcoma (64.8%), leiomyosarcoma (94.1%), neurosarcoma (68.9%) or fibrosar-
coma (71.1%). Furthermore, overall survival was lower than
50% in patients with undifferentiated sarcoma (35.2%) and
synovial sarcoma (41%) (Table II). There was a similar trend
for 5-year metastasis-free survival. However, the low number
of patients for each tumour type group did not allow a
correct statistical analysis. Moreover, distribution of tumour
grade was different according to tumour type; grade 3 were
more frequent in the histologic types with the poorest prog-
nostic such as undifferentiated sarcoma or synovial sarcoma.
Grade Tumour grade was found to be strongly correlated
with overall survival (P<0.0001) (Figure 5), disease-free sur-
vival (P= 0.0003) and metastasis-free survival (P<0.001)
(Figure 6). No patient with a grade 1 lesion presented a
metastatic relapse at the time of analysis.
Macroscopic margins A macroscopic tumour residue was
left in seven patients after surgery. These patients had a
Table III Stepwise Cox's multivariate analysis for prognostic factors in overall
survival (Mantel-Cox)
Variable entered Log Global
Step (code) likelihood chi-square P value
0 - 136.741
1 Grade - 126.472 19.725 0.0000089
(grade I = 1; grade 2 = 2; grade 3 = 3)
2 Tumour Depth - 120.534 29.672 0.0000003
(O = superficial; I = deep)
3 Tumour site - 118.010 34.562 0.0000001
(0= non-limb; I = limb)
No other term (tumour size, invasion of neurovascular structures or bone, macroscopic margins) passes the remove and enter limits (0.10; 0.05)
Coeff/standard
Variable Coeff. error Exp (coeff.) P value
Grade 1.3348 4.5983 3.7994 0.000004
Tumour depth 1.6414 3.0157 5.1624 0.0025
Tumour site - 0.8296 - 2.2459 0.4362 0.025
I .
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Table IV Stepwise Cox's multivariate analysis for prognostic
factors in disease-free survival (Mantel-Cox)
Variable entered Log Global
Step (code) likelihood chi-square P value
0 - 209.589
1 Grade -201.181 16.5 0.00005
(grade 1 = 1; grade 2 = 2; grade 3 = 3)
2 Tumour size - 196.696 24.898 0.000004
(0=<Scm; 1= 5cm)
No other term (tumour location, tumour depth, invasion of neuro-
vascular structures or bone, macroscopic margins) passes the remove
and enter limits (0.10; 0.05)
Coeff/standard
Variable error Exp (coeff.) P value
Grade 4.0460 2.4072 0.00005
Tumour site 2.7321 2.7723 0.006
Table V Stepwise Cox's multivariate analysis for prognostic factors in metastasis-free
survival (Mantel-Cox)
Variable entered Log Global
Step (code) likelihood chi-square P value
0 149.366
1 Grade - 137.771 22.155 0.0000025
(grade 1 = 1; grade 2 = 2; grade 3 = 3)
2 Tumour Depth - 129.393 36.190 0.00000001
(0 = superficial; 1 = deep)
No other term (tumour location, tumour size, invasion of neurovascular structures or
bone, macroscopic margins) passes the remove and enter limits (0.10; 0.05)
Coeff/standard
Variable Coeff. error Exp (coeff.) P value
Grade 1.31 4.5854 7.0413 0.0000046
Tumour depth 1.95 3.2021 3.7065 0.0013
Table VI Stepwise Cox's multivariate analysis for prognostic
factors in local recurrence-free survival (Mantel-Cox)
Variable entered Log Global
Step (code) likelihood chi-square P value
0 - 110.916
1 Macroscopic margins - 106.135 18.687 0.000015
(0 = negative; 1 = positive)
2 Sex - 102.591 25.702 0.0000026
(1 = male; 2 = female)
No other term (tumour location, tumour size, tumour depth, grade,
invasion of neurovascular structures) passes the remove and enter
limits (0.10; 0.05)
Coeff/standard
Variable error Exp (coeff.) P value
Macroscopic margins 3.8309 7.1997 0.00013
Sex 2.5507 3.0040 0.01
lower overall survival (P<0.0001), disease-free survival (P
<0.0001) and metastasis-free survival (P = 0.04).
AJC/UICC classification Prognostic groups established ac-
cording to tumour size, local tumour invasiveness, tumour
grade, and node status according to the AJC/UICC classi-
fication were predictive for overall survival (Figure 7),
metastasis-free survival (Figure 8) and disease-free survival.
There was no significant difference between stage III and
stage IVa, but this latter subgroup is poorly represented in
this study owing to patient selection. The AJC/UICC appears
to be more discriminating for prognostic evaluation than
Hajdu's classification, which considers tumour size, grade
and depth, where no significant difference appeared between
stage 0, I or II. However, there was a significant difference in
overall survival (P = 0.0006), disease-free survival
(P = 0.0007) and metastasis-free survival (P = 0.0001)
between stages II and III.
Multivanate analysis (Tables III, IV, V, VI)
The six prognostic variables (tumour site, tumour size,
tumour depth, invasion of neurovascular structures or bone,
grade and macroscopic margins) found to be significantly
correlated with evolution in univariate analysis were selected
for a Cox's stepwise multivariate analysis. This analysis was
done in 131 patients with no missing data. Tumour grade,
and tumour depth was the most significant predictive vari-
ables for metastasis-free survival (Table III). Furthermore,
these two variables and tumour site were predictive factors
for overall survival (Table IV). On the other hand, macro-
scopic margins and sex were significant for local recurrence
(Table VI).
According to the end points considered in this study, each
patient with STS could be scored for MFS and OS, consider-
ing the coefficient value of each significant variable deter-
mined by Cox's multivariate analysis (Table III, V).PROGNOSTIC VARIABLES IN OPERABLE SOFT TISSUE SARCOMAS 967
Table VII Prognostic score in metastasis-free survival according to the stepwise Cox's multivariate analysis (Table V)
Tumour grade Tumour depth Increasing
grade I = 1; grade 2 = 2; grade 3 = 3 superficial = 0; deep =0 metastatic
Tumour characteristics coefficient: 1.31 coefficient: 1.95 Score risk
Grade 1 and superficial I x 1.31 + 0 x 1.95 = 1.31
Grade 2 and superficial 2 x 1.31 + 0 x 1.95 = 2.62
Grade 1 and deep 1 x 1.31 + 1 x 1.95 = 3.26
Grade 3 and superficial 3 x 1.31 + 0 x 1.95 = 3.93
Grade 2 and deep 2 x 1.31 + I x 1.95 = 4.57
Grade 3 and deep 3 x 1.31 + 1 x 1.95 = 5.88
<, / Grade 1 + Sup. grade 2
I1, p = 0.0005
I'...,Deep grade 2 + Sup. grade 3
II p =0.003
I,
Deep grade 3
0 12 24 36 48 60 72 84 96 108 120
Months
Figure 9 Overall survival according to prognostic groups. Grade
1 + superficial grade 2 (49 pts), deep grade 2 + superficial grade 3
(52 pts), deep grade 3 (30 pts).
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Figure 10 Metastasis-free survival according to prognostic
groups. Grade 1 + superficial grade 2 (49 pts), deep grade
2 + superficial grade 3 (52 pts), deep grade 3 (30 pts).
For example, Table VII represents the increasing metas-
tatic risk for this series. Consequently, tumour grade and
deepness were considered for a prognostic stratification and
allowed classification of patients into three groups. A favor-
able prognostic group included patients with grade 1 tumour
or superficial, grade 2 tumour and had a 5-year corrected
survival rate of 97.8% and a 5-year metastasis-free survival
rate of 100% (Figure 9, 10). An intermediate prognostic
group with patients, with deep, grade 2 tumour or superficial,
grade 3 tumour, had a 5-year overall survival rate of 58.8%
and a 5-year metastasis-free survival of 48.1 %. Finally, a
poor prognostic group defined as patients with deep grade 3
tumour had a 5-year survival rate of 31.7% and a 5-year
metastasis-free survival of 34.1 %.
Discussion
Whether adjuvant chemotherapy is of benefit or not in
patients with operable STS remains a matter of controversy
(Elias, 1989; Ravaud et al., 1990). Among the reasons which
can be called upon to explain the discrepancies in results
from the different clinical trials performed, there is the
difference in the selection of poor risk patients, owing to
differences in evaluation of prognostic variables (Coindre et
al., 1986; Collin et al., 1987; Costa et al., 1984; Enzinger,
1983; Hajdu, 1979; Heise et al., 1986; Lack et al., 1989;
Mandard et al., 1989; Markhede et al., 1982; Potter et al.,
1986; Presant et al., 1986; Russel, 1977; Shiraki et al., 1989;
Stotter et al., 1990; Trojani et al., 1984; Tsujimoto, 1988;
Ueda et al., 1988). This study confirms that the evolution of
patients with an operable STS depends mainly on the even-
tual advent of metastatic disease: of the 34 patients who died
from sarcoma, death was due to a metastatic spread in 30/34
patients (88.3%) and only 4/34 patients (11.3%) died of local
tumour evolution. Therefore, the main end point to define
high-risk patients must be metastasis-free survival rather than
overall survival or disease-free survival. In this study, the
prognostic variables which confer the highest relative risk for
metastatic disease were tumour grade and tumour depth.
These variables have also been found of prognostic impor-
tance in previous studies, although dealing with other patient
selection criteria (Trojani et al., 1984).
In this series, tumour location (limb tumours versus non-
limb tumours) had an impact only on overall survival. The
only point which could explain the difference in overall sur-
vival, while no significant difference in local recurrence and
metastatic rate was found, was a better outcome following
rescue treatments in patients with an extremity tumour who
experienced a local relapse. That may also be due in part to
the patient selection modalities used to allow a primarily
conservative surgery. Patients who did not fit those selection
criteria were included in another treatment program with
systematic neoadjuvant chemotherapy; among those patients,
62% had non-limb tumours (Ravaud et al., 1990).
Previous studies have pointed out other significant prog-
nostic variables such as tumour size, invasion of adjacent
neurovascular structures or bone, histopathological types and
surgical margins.
In this series as in others (Collin et al., 1987; Heise et al.,
1986; Lack et al., 1989; Markhede et al., 1982; Potter et al.,
1986; Trojani et al., 1984) tumour histopathological type was
difficult to correlate with prognostic, although better prog-
nostic was associated with certain types, while others like
synovial sarcoma or undifferentiated sarcoma were more
ominous. However, the rarity of sarcomas and the multi-
plicity of tumour types and subtypes lead to considerable
difficulty in pathological classification (Coindre et al., 1986;
Presant et al., 1986; Shiraki et al., 1989). Moreover, as results
of tumour histopathological classification are highly variable
from one pathologist to another, a prognostic evaluation
based on tumour type appears hazardous. In fact, his-
topathological type has already been reported to be less
predictive of the evolution of sarcoma than tumour grade
(Markhede et al., 1982).
In this series as in others (Coindre et al., 1986; Collin et
al., 1987; Costa et al., 1984; Enzinger, 1983; Hajdu, 1979;
Heise et al., 1986; Lack et al., 1989; Mandard et al., 1989;
Markhede et al., 1982; Potter et al., 1986; Presant et al.,
1986; Russell, 1977; Shiraki et al., 1989; Stotter et al., 1990;
Trojani et al., 1984; Tsujimoto, 1988; Ueda et al., 1988),
tumour grade was found to be the most important single
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prognostic variable correlated with survival and metastasis-
free survival. However, grading of STS can be done by
various means (Coindre et al., 1986; Costa et al., 1985;
Enzinger, 1983; Hajdu, 1979; Russell, 1977; Trojani et al.,
1984), and this can result in discrepancies in the resulting
grades (Coindre et al., 1986; Mandard et al., 1989). There-
fore, with the prognostic importance devoted to this variable
in STS, it is necessary to establish a consensus on sarcoma
grading. Among the other prognostic variables, tumour
depth was the only clinical prognostic variable selected by the
multivariate analysis in this study. The importance of this
variable has been pointed out by Hadju (1977). However, the
present study considers evaluation of these prognostic vari-
ables according to Hadju's classification and found poor
discrimination between intermediate and good prognostic
groups.
Other variables which are used in the AJC/UICC staging
system were predictive in overall survival and metastasis-free
survival but were not found significant by multivariate
analysis. Once again, this may be due mainly to patient
selection for this series, with patients with T3 tumours or the
largest tumours being preferably treated with chemotherapy
before surgery in our institution. Therefore, the latter pa-
tients are under represented with only 17 patients with a
vascular or bone involvement. Moreover node involvement is
known to result in poor prognostic (Bui et al., 1987; Russell
et al., 1977), but is rare at presentation in STS; only one
patient had such an initial node involvement in this series
which excluded patients presenting with a recurrence.
Despite these remarks, the AJC/UICC staging system has
been found in this study to be predictive in overall survival
and metastasis-free survival. However, analysis revealed a
large prognostic disparity among patients especially for pa-
tients with intermediate outcome. Using tumor depth, it was
possible to discriminate from among those patients with
stage II disease, those with a grade 2 superficial tumour who
had a low metastatic risk and an overall survival comparable
to patients with grade 1 tumour and those with a deep
tumour grade 2, who had a high metastatic risk and a
prognostic similar to patients with grade 3 tumours.
Therefore, a prognostic combination of tumour depth with
the variables of the AJC/UICC classification, was found to
be useful for practical prognosis in STS patients. Those with
a grade 3 tumour or a deep grade 2 lesion or a neurovascular
or bone involvement have a high metastatic risk and poor
outcome. They represent the population of sarcoma patients
who should be considered for adjuvant chemotherapy trials
(Elia et al., 1989; Ravaud et al., 1990).
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